Modulation of experimental autoimmune uveitis with cyclosporin A

Archives of Ophthalmology
R B NussenblattW B Wacker

Abstract

Cyclosporin A has been shown to be an effective inhibitor of T cell-mediated diseases. We show here that cyclosporin A was capable of totally preventing the clinical appearance of experimental autoimmune uveitis in Lewis rats, even when administered on an every-other-day schedule (10 mg/kg) or when begun seven days after immunization (40 mg/kg). At lower doses of the drug, a modulation of the disease was seen with evidence of a more chronic, granulomatous process. A long-lasting unresponsive state to the immunizing antigen was not uniformly induced with cyclosporin A if therapy was begun seven days after S antigen immunization. Because of cyclosporin A's effective control of this experimental model that is induced by an antigen to which certain patients with uveitis demonstrate cell-mediated immune responses, cyclosporin A may be an effective mode of therapy for T cell-mediated intraocular inflammatory disease.

Citations

May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·N A CacalanoB F Erlanger
Jun 1, 1990·The British Journal of Ophthalmology·J de VriesA Kijlstra
Feb 1, 1990·Clinical and Experimental Immunology·C Grönhagen-RiskaT Törnroth
Jun 1, 1990·The British Journal of Ophthalmology·D BenEzraP Timonen
Apr 1, 1986·Annals of the Rheumatic Diseases·K TakagishiK Arai
May 1, 1984·The Journal of Experimental Medicine·N KaibaraS Jingushi
Dec 1, 1983·The Journal of Experimental Medicine·N KaibaraI Katsuki
Nov 26, 2002·The British Journal of Ophthalmology·A D Dick
Dec 24, 2009·Indian Journal of Ophthalmology·D MathewsN P Jones
Apr 27, 2013·BMC Ophthalmology·Alastair K Denniston, Andrew D Dick
Oct 1, 1984·Agents and Actions·A W ThomsonJ G Simpson
Mar 26, 2004·Transplantation Proceedings·D A HesselinkP M van Hagen
Jan 1, 1989·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·M ZierhutU Pleyer
Jan 1, 1994·Ocular Immunology and Inflammation·J U BreeveldA Kijlstra
Sep 1, 1995·Current Eye Research·L V Rizzo, R R Caspi
Aug 20, 2015·The British Journal of Ophthalmology·Shreya S PrabhuTheresa M Cooney
Sep 25, 2004·Progress in Retinal and Eye Research·Andrew D DickAndrew P Cope
Nov 1, 1986·Survey of Ophthalmology·R B Nussenblatt, A G Palestine
Mar 14, 2017·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Wendy M Smith
Feb 1, 1985·Clinical Immunology and Immunopathology·D B DrachmanA Pestronk
Dec 1, 2017·Ophthalmology and Therapy·Srilakshmi M SharmaKanmin Xue
Jan 15, 1985·The Journal of Comparative Neurology·K V FiteP Doran
Jan 1, 1985·Journal of Ocular Pharmacology·R B NussenblattC C Chan
Jan 1, 1990·Journal of Ocular Pharmacology·R T WuY M Chung
Jan 1, 1987·Acta Ophthalmologica. Supplement·K MahlbergT Tallberg
Nov 30, 1993·Annals of the New York Academy of Sciences·S M Whitcup, R B Nussenblatt
Feb 1, 1985·Drug Intelligence & Clinical Pharmacy·R J PtachcinskiR Venkataramanan
Aug 1, 1984·Acta Ophthalmologica·K Karjalainen
Oct 26, 2018·Frontiers in Immunology·Igal Gery, Rachel R Caspi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.